Vertex Pharmaceuticals’ ALYFTREK Approved for Cystic Fibrosis, Marks New Treatment Era
Vertex Pharmaceuticals has received approval for its new cystic fibrosis treatment, ALYFTREK, a once-daily triple combination CFTR modulator, marking a significant milestone in the company’s pursuit of innovative treatments for the disease.
2 minutes to read